Quality of life with biweekly docetaxel and capecitabine in advanced gastro-oesophageal cancer.

Autor: Korkeila EA; Department of Oncology, University of Turku and Turku University Hospital, Hämeentie 11, PB 52, FI-20521, Turku, Finland. eija.korkeila@tyks.fi., Salminen T; Department of Oncology, Tampere University and Tampere University Hospital, Tampere, Finland., Kallio R; Department of Oncology and Haematology, Oulu University and Oulu University Hospital, Oulu, Finland., Mikkola M; Department of Oncology, Vaasa Central Hospital, Vaasa, Finland., Auvinen P; Faculty of Medicine and Cancer Center and Department of Oncology, University of Eastern Finland, Kuopio University Hospital, Kuopio, Finland., Pyrhönen S; Department of Oncology, University of Turku and Turku University Hospital, Hämeentie 11, PB 52, FI-20521, Turku, Finland., Ristamäki R; Department of Oncology, University of Turku and Turku University Hospital, Hämeentie 11, PB 52, FI-20521, Turku, Finland.

Publikováno v: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2017 Sep; Vol. 25 (9), pp. 2771-2777. Date of Electronic Publication: 2017 Apr 20.

Disease outcome of patients with pancreatic cancer in a cohort treated outside clinical trials.

Autor: Koskela HM; Department of Oncology and Radiotherapy, Turku University Hospital, Hämeentie 11, PB 52, FIN-20521 Turku, Finland. eija.korkeila@tyks.fi or eijakorkeila@gmail.com., Syrjänen KJ, Korkeila EA

Publikováno v: Anticancer research [Anticancer Res] 2013 Dec; Vol. 33 (12), pp. 5491-4.

Lack of CD44 variant 6 expression in rectal cancer invasive front associates with early recurrence.

Autor: Avoranta ST; Department of Oncology and Radiotherapy, University of Turku and Turku University Hospital, FIN-20521 Turku, Finland. stavor@utu.fi, Korkeila EA, Syrjänen KJ, Pyrhönen SO, Sundström JT

Publikováno v: World journal of gastroenterology [World J Gastroenterol] 2012 Sep 07; Vol. 18 (33), pp. 4549-56.

Securin identifies a subgroup of patients with poor outcome in rectal cancer treated with long-course (chemo)radiotherapy.

Autor: Avoranta ST; Department of Oncology and Radiotherapy, University of Turku, Turku University Hospital, Finland. stavor@utu.fi, Korkeila EA, Minn HR, Syrjänen KJ, Pyrhönen SO, Sundström JT

Publikováno v: Acta oncologica (Stockholm, Sweden) [Acta Oncol] 2011 Nov; Vol. 50 (8), pp. 1158-66.